Electrochemical biosensor based on antibody-modified Au nanoparticles for rapid and sensitive analysis of influenza A virus

Bao, Qiwen; Yang, Zhengchun; Li, Jun; Wang, Hanjie; Pang, Gaoju; Guo, Qianjin; Wei, Jun; Cheng, Weiguo; Li, Gang

doi:10.1007/s11581-023-04944-w

Cited by 9 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, the performances of such biosensors were compared with other H1N1 electrochemical biosensors in Table S3, wherein the LOD of electrochemical biosensors proposed by Manohara Reddy et al, 27 Park et al, 28 and Bhardwaj et al 53 reached nanomolar (3.09 nM), picomolar (10 pM), and nanomolar (3.45 nM), respectively. The LOD of this sensor increased by 8.974 and 0.224 pg/mL compared to Bai et al 54 and Bao et al, 55 which demonstrated that the electrochemical biosensor in this study exhibited a wide linear range and a lower LOD (1.01 fM). It was probably due to the improved conductivity and higher electroactive surface area of the COFs/MWCNT nanocomposites.…”

Section: Specificity and Stability Of Biosensorsmentioning

confidence: 42%

Covalent Organic Frameworks/MWCNT Nanocomposites for Electrochemical Detection of the H1N1 Influenza Virus

Yan,

Zhang,

Cheng

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

H1N1 influenza is highly contagious and can cause zoonotic respiratory disease. Thus, early detection is essential to prevent and control its rapid spread in the population. Given the limitations of traditional detection methods in clinical laboratories, an electrochemical biosensor modified with TAPT-TP COFs/MWCNT nanomaterial (TAPT: 4,4′,3,4, trianiline; TP: 1,3,5-Triformylphloroglucinol; MWCNTs: Multiwalled carbon nanotubes), dualprobe-specific recognizer and signal amplifier was reported, which was capable of quantifying H1N1 virus complementary DNA (cDNA) from 10 fM to 1 nM (limit of detection, LOD = 1.01 fM) with distinguished selectivity and reproducibility. Furthermore, the portable device achieved a detection range of 1 fM to 1 pM and LOD of 0.17 fM, and the accuracy was confirmed by spiked recovery experiments (recovery: 98.01−101.24%). The applicability of the portable biosensing device was verified by quantifying the concentration of H1N1 virus in the nasal turbinates and lung tissue of mice, the results of which were compared with droplet PCR (ddPCR) to validate its reliability (P > 0.05) and confirm its potential application in influenza surveillance. Thus, the above biosensor can help doctors or other professionals obtain rapid and accurate monitoring results and is expected to realize the on-site diagnosis of the H1N1 influenza virus for early intervention and epidemic management.

show abstract

Section: Specificity and Stability Of Biosensorsmentioning

confidence: 42%

Covalent Organic Frameworks/MWCNT Nanocomposites for Electrochemical Detection of the H1N1 Influenza Virus

Yan,

Zhang,

Cheng

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…Nowadays, AuNPs are used for the ultrasensitive detection of varied targets [29] such as enzymes [30,31], proteins [32], DNA [33,34], cells [35], viruses [36][37][38][39][40][41], and bacteria [42,43]. Moreover, promising therapeutic approaches have just begun using AuNPs as antiviral agents capable of trapping viruses [44][45][46][47], in anticoagulant therapy [48], in photothermal therapy for breast cancer [49], and in the treatment of inflammatory bowel disease [50].…”

Section: Introductionmentioning

confidence: 99%

Updates on the Biofunctionalization of Gold Nanoparticles for the Rapid and Sensitive Multiplatform Diagnosis of SARS-CoV-2 Virus and Its Proteins: From Computational Models to Validation in Human Samples

Ionescu

2023

IJMS

View full text Add to dashboard Cite

Since the outbreak of the pandemic respiratory virus SARS-CoV-2 (COVID-19), academic communities and governments/private companies have used several detection techniques based on gold nanoparticles (AuNPs). In this emergency context, colloidal AuNPs are highly valuable easy-to-synthesize biocompatible materials that can be used for different functionalization strategies and rapid viral immunodiagnosis. In this review, the latest multidisciplinary developments in the bioconjugation of AuNPs for the detection of SARS-CoV-2 virus and its proteins in (spiked) real samples are discussed for the first time, with reference to the optimal parameters provided by three approaches: one theoretical, via computational prediction, and two experimental, using dry and wet chemistry based on single/multistep protocols. Overall, to achieve high specificity and low detection limits for the target viral biomolecules, optimal running buffers for bioreagent dilutions and nanostructure washes should be validated before conducting optical, electrochemical, and acoustic biosensing investigations. Indeed, there is plenty of room for improvement in using gold nanomaterials as stable platforms for ultrasensitive and simultaneous “in vitro” detection by the untrained public of the whole SARS-CoV-2 virus, its proteins, and specific developed IgA/IgM/IgG antibodies (Ab) in bodily fluids. Hence, the lateral flow assay (LFA) approach is a quick and judicious solution to combating the pandemic. In this context, the author classifies LFAs according to four generations to guide readers in the future development of multifunctional biosensing platforms. Undoubtedly, the LFA kit market will continue to improve, adapting researchers’ multidetection platforms for smartphones with easy-to-analyze results, and establishing user-friendly tools for more effective preventive and medical treatments.

show abstract

“…This methodology has limitations for mass testing applications due to long turnaround times and the need for sophisticated equipment and trained personnel. Electrochemical biosensors have previously been used for the detection of influenza − viruses (see Supporting Materials (SM) Table S2) and are rapidly emerging as an alternative to conventional clinical screening techniques. These sensing systems are simple, accurate, and possess a low limit of detection.…”

mentioning

confidence: 99%

Rapid Direct Detection of SARS-CoV-2 Aerosols in Exhaled Breath at the Point of Care

Ghumra,

Shetty,

McBrearty

et al. 2023

ACS Sens.

View full text Add to dashboard Cite

Airborne transmission via virus-laden aerosols is a dominant route for the transmission of respiratory diseases, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Direct, non-invasive screening of respiratory virus aerosols in patients has been a long-standing technical challenge. Here, we introduce a point-of-care testing platform that directly detects SARS-CoV-2 aerosols in as little as two exhaled breaths of patients and provides results in under 60 s. It integrates a hand-held breath aerosol collector and a llama-derived, SARS-CoV-2 spike-protein specific nanobody bound to an ultrasensitive microimmunoelectrode biosensor, which detects the oxidation of tyrosine amino acids present in SARS-CoV-2 viral particles. Laboratory and clinical trial results were within 20% of those obtained using standard testing methods. Importantly, the electrochemical biosensor directly detects the virus itself, as opposed to a surrogate or signature of the virus, and is sensitive to as little as 10 viral particles in a sample. Our platform holds the potential to be adapted for multiplexed detection of different respiratory viruses. It provides a rapid and non-invasive alternative to conventional viral diagnostics.

show abstract

Electrochemical biosensor based on antibody-modified Au nanoparticles for rapid and sensitive analysis of influenza A virus

Cited by 9 publications

References 33 publications

Covalent Organic Frameworks/MWCNT Nanocomposites for Electrochemical Detection of the H1N1 Influenza Virus

Covalent Organic Frameworks/MWCNT Nanocomposites for Electrochemical Detection of the H1N1 Influenza Virus

Updates on the Biofunctionalization of Gold Nanoparticles for the Rapid and Sensitive Multiplatform Diagnosis of SARS-CoV-2 Virus and Its Proteins: From Computational Models to Validation in Human Samples

Rapid Direct Detection of SARS-CoV-2 Aerosols in Exhaled Breath at the Point of Care

Contact Info

Product

Resources

About